1
|
Oliveira D, Martins A, Martins F, Rato M, Pinheiro F, Fonseca D, Vaz C, Mariz E, Costa L. Wunderlich syndrome as a rare complication of polyarteritis nodosa: a case report. Reumatismo 2024; 76. [PMID: 38523579 DOI: 10.4081/reumatismo.2024.1669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Accepted: 01/02/2024] [Indexed: 03/26/2024] Open
Abstract
Spontaneous subcapsular and perirenal hemorrhage, known as Wunderlich syndrome (WS), is a rare clinical manifestation of polyarteritis nodosa (PAN). We report a case of a 48-year-old male with a history of recurrent episodes of leg muscle tenderness and dysesthesia, bilateral flank pain, painful nodular skin lesions in the lower limbs, weight loss, and difficult-to-control arterial hypertension. The abdominopelvic computed tomography angiography showed a large left perirenal hematoma, leading to the patient's admission to the intensive care unit. After the exclusion of infectious or neoplastic foci, the patient was diagnosed with PAN and started intravenous methylprednisolone pulses with a good response. Since WS is a rare initial clinical manifestation of PAN, an early diagnosis and aggressive treatment will significantly improve clinical outcomes.
Collapse
Affiliation(s)
- D Oliveira
- Rheumatology Department, São João University Hospital Center, Porto; Center for Health Technology and Services Research, Faculty of Medicine, University of Porto.
| | - A Martins
- Rheumatology Department, São João University Hospital Center, Porto.
| | - F Martins
- Rheumatology Department, University Hospital Center of the Algarve, Faro.
| | - M Rato
- Rheumatology Department, São João University Hospital Center, Porto; Department of Medicine, Faculty of Medicine, University of Porto.
| | - F Pinheiro
- Rheumatology Department, São João University Hospital Center, Porto.
| | - D Fonseca
- Rheumatology Department, Vila Nova de Gaia/Espinho Hospital Center, Gaia.
| | - C Vaz
- Rheumatology Department, São João University Hospital Center, Porto; Center for Health Technology and Services Research, Faculty of Medicine, University of Porto; Department of Medicine, Faculty of Medicine, University of Porto.
| | - E Mariz
- Rheumatology Department, São João University Hospital Center, Porto; Department of Medicine, Faculty of Medicine, University of Porto.
| | - L Costa
- Rheumatology Department, São João University Hospital Center, Porto.
| |
Collapse
|
2
|
Martins F, Rosspopoff O, Carlevaro-Fita J, Forey R, Offner S, Planet E, Pulver C, Pak H, Huber F, Michaux J, Bassani-Sternberg M, Turelli P, Trono D. A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. Cancer Res 2024; 84:808-826. [PMID: 38345497 PMCID: PMC10940857 DOI: 10.1158/0008-5472.can-23-1237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 10/15/2023] [Accepted: 01/19/2024] [Indexed: 03/16/2024]
Abstract
Heterochromatin loss and genetic instability enhance cancer progression by favoring clonal diversity, yet uncontrolled replicative stress leads to mitotic catastrophe and inflammatory responses that promote immune rejection. KRAB domain-containing zinc finger proteins (KZFP) contribute to heterochromatin maintenance at transposable elements (TE). Here, we identified an association of upregulation of a cluster of primate-specific KZFPs with poor prognosis, increased copy-number alterations, and changes in the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL). Depleting two of these KZFPs targeting evolutionarily recent TEs, ZNF587 and ZNF417, impaired the proliferation of cells derived from DLBCL and several other tumor types. ZNF587 and ZNF417 depletion led to heterochromatin redistribution, replicative stress, and cGAS-STING-mediated induction of an interferon/inflammatory response, which enhanced susceptibility to macrophage-mediated phagocytosis and increased surface expression of HLA-I, together with presentation of a neoimmunopeptidome. Thus, cancer cells can exploit KZFPs to dampen TE-originating surveillance mechanisms, which likely facilitates clonal expansion, diversification, and immune evasion. SIGNIFICANCE Upregulation of a cluster of primate-specific KRAB zinc finger proteins in cancer cells prevents replicative stress and inflammation by regulating heterochromatin maintenance, which could facilitate the development of improved biomarkers and treatments.
Collapse
Affiliation(s)
- Filipe Martins
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Clinics of Medical Oncology, Cantonal Hospital of Fribourg (HFR), Fribourg, Switzerland
| | - Olga Rosspopoff
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Joana Carlevaro-Fita
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Romain Forey
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Sandra Offner
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Evarist Planet
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Cyril Pulver
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - HuiSong Pak
- Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- Agora Cancer Research Centre, Lausanne, Switzerland
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
| | - Florian Huber
- Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- Agora Cancer Research Centre, Lausanne, Switzerland
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
| | - Justine Michaux
- Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- Agora Cancer Research Centre, Lausanne, Switzerland
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
| | - Michal Bassani-Sternberg
- Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- Agora Cancer Research Centre, Lausanne, Switzerland
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
| | - Priscilla Turelli
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Didier Trono
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| |
Collapse
|
3
|
Rosspopoff O, Martins F, Trono D. New ingredients for old recipes. Nat Genet 2023; 55:2023-2024. [PMID: 37973954 DOI: 10.1038/s41588-023-01591-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Affiliation(s)
- Olga Rosspopoff
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Filipe Martins
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Didier Trono
- School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
| |
Collapse
|
4
|
Mauro E, Lapaillerie D, Tumiotto C, Charlier C, Martins F, Sousa SF, Métifiot M, Weigel P, Yamatsugu K, Kanai M, Munier-Lehmann H, Richetta C, Maisch M, Dutrieux J, Batisse J, Ruff M, Delelis O, Lesbats P, Parissi V. Modulation of the functional interfaces between retroviral intasomes and the human nucleosome. mBio 2023; 14:e0108323. [PMID: 37382440 PMCID: PMC10470491 DOI: 10.1128/mbio.01083-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 05/16/2023] [Indexed: 06/30/2023] Open
Abstract
Infection by retroviruses as HIV-1 requires the stable integration of their genome into the host cells. This process needs the formation of integrase (IN)-viral DNA complexes, called intasomes, and their interaction with the target DNA wrapped around nucleosomes within cell chromatin. To provide new tools to analyze this association and select drugs, we applied the AlphaLISA technology to the complex formed between the prototype foamy virus (PFV) intasome and nucleosome reconstituted on 601 Widom sequence. This system allowed us to monitor the association between both partners and select small molecules that could modulate the intasome/nucleosome association. Using this approach, drugs acting either on the DNA topology within the nucleosome or on the IN/histone tail interactions have been selected. Within these compounds, doxorubicin and histone binders calixarenes were characterized using biochemical, in silico molecular simulations and cellular approaches. These drugs were shown to inhibit both PFV and HIV-1 integration in vitro. Treatment of HIV-1-infected PBMCs with the selected molecules induces a decrease in viral infectivity and blocks the integration process. Thus, in addition to providing new information about intasome-nucleosome interaction determinants, our work also paves the way for further unedited antiviral strategies that target the final step of intasome/chromatin anchoring. IMPORTANCE In this work, we report the first monitoring of retroviral intasome/nucleosome interaction by AlphaLISA. This is the first description of the AlphaLISA application for large nucleoprotein complexes (>200 kDa) proving that this technology is suitable for molecular characterization and bimolecular inhibitor screening assays using such large complexes. Using this system, we have identified new drugs disrupting or preventing the intasome/nucleosome complex and inhibiting HIV-1 integration both in vitro and in infected cells. This first monitoring of the retroviral/intasome complex should allow the development of multiple applications including the analyses of the influence of cellular partners, the study of additional retroviral intasomes, and the determination of specific interfaces. Our work also provides the technical bases for the screening of larger libraries of drugs targeting specifically these functional nucleoprotein complexes, or additional nucleosome-partner complexes, as well as for their characterization.
Collapse
Affiliation(s)
- E. Mauro
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| | - D. Lapaillerie
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| | - C. Tumiotto
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| | - C. Charlier
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Nantes Université, CNRS, US2B, UMR 6286 and CHU Nantes, Inserm, CNRS, SFR Bonamy, IMPACT Platform, Nantes, France
| | - F. Martins
- UCIBIO@REQUIMTE, BioSIM Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro, Porto, Portugal
| | - S. F. Sousa
- UCIBIO@REQUIMTE, BioSIM Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro, Porto, Portugal
| | - M. Métifiot
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| | - P. Weigel
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Nantes Université, CNRS, US2B, UMR 6286 and CHU Nantes, Inserm, CNRS, SFR Bonamy, IMPACT Platform, Nantes, France
| | - K. Yamatsugu
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - M. Kanai
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - H. Munier-Lehmann
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Institut Pasteur, Unité de Chimie et Biocatalyse, CNRS UMR 3523, Paris, France
| | - C. Richetta
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France
| | - M. Maisch
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS, UMR8104, Paris, France
| | - J. Dutrieux
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS, UMR8104, Paris, France
| | - J. Batisse
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Département de Biologie Structurale intégrative, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), UDS, U596 INSERM, UMR7104, CNRS, Strasbourg, France
| | - M. Ruff
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- Département de Biologie Structurale intégrative, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), UDS, U596 INSERM, UMR7104, CNRS, Strasbourg, France
| | - O. Delelis
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
- LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France
| | - P. Lesbats
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| | - V. Parissi
- Fundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux, France
- Viral DNA Integration and Chromatin Dynamics Network (DyNAVir), Bordeaux, France
| |
Collapse
|
5
|
Verla W, Barratt R, Chan G, Campos-Juanatey F, Esperto F, Greenwell T, Lumen N, Martins F, Osman N, Ploumidis A, Riechardt S, Waterloos M, Dimitropoulos K. Is a course of Intermittent Self-Dilatation (ISD) with topical corticosteroids superior at stabilising urethral stricture disease in men and improving functional outcomes over a course of ISD alone? A systematic review and meta-analysis. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01051-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
6
|
Tryfonyuk L, Castro A, Bernal J, Iatsyna O, Martins F. Outcomes of primary surgical treatment in advanced peyronie’s disease: A multi-institutional study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00877-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Muacevic A, Adler JR, Tenreiro N, Martins F. Adenopathies: A Confusing Presentation of Primary Biliary Cholangitis. Cureus 2023; 15:e33814. [PMID: 36819325 PMCID: PMC9930001 DOI: 10.7759/cureus.33814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2023] [Indexed: 01/19/2023] Open
Abstract
Primary biliary cholangitis (PBC) is an autoimmune disease in which the intrahepatic bile ducts are destroyed. Its symptoms include chronic fatigue, pruritus, steatorrhea, and jaundice, with variable clinical course. We are introducing a case of a 65-year-old woman with anorexia, weight loss, asthenia, and pruritus. The imaging studies revealed dilatation of the intrahepatic and common bile ducts and adenopathies at the level of the hepatoduodenal ligament, histologically compatible with reactive lymphadenitis. After the exclusion of neoplasia, she was referred to Internal Medicine where positivity was obtained for anti-mitochondrial autoantibodies suggestive of PBC. After the initiation of therapy, there was a resolution of the clinical symptoms and the adenopathies were no longer detected in subsequent studies. The authors intend to highlight this case, especially due to the presence of adenopathies and constitutional symptoms where PBC should also be considered, as a differential diagnosis.
Collapse
|
8
|
Nicolau R, Martins A, Oliveira D, Samões B, Martins F, Pinheiro F, Rato M, Bernardes M, Costa L. Impact de l’infection par le SARS-CoV-2 sur l’activité de la maladie des patients atteints de rhumatisme psoriasique sous bDMARD : données réelles. Rev Rhum Ed Fr 2022. [PMCID: PMC9758747 DOI: 10.1016/j.rhum.2022.10.401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Introduction L’infection par le SARS-CoV-2 peut entraîner une inflammation sévère et il a été suggéré d’induire des poussées de rhumatisme psoriasique (RP). Cependant, l’impact sur l’activité de la maladie et la réponse aux DMARD biologiques modificateurs de la maladie (bDMARD) reste inconnu. Patients et méthodes Nous avons réalisé une analyse rétrospective incluant tous les patients atteints de RP, répondant aux critères CASPAR et sous biothérapie, suivis dans le service de rhumatologie d’un CHU universitaire tertiaire. Les données démographiques et cliniques, y compris la survenue d’une infection par le SARS-CoV-2, ont été collectées à partir de notre base de données nationale (reuma.pt). L’activité de la maladie (CDAI, SDAI, DAS28 4v, BASDAI, ASDAS) et les réponses aux bDMARD (réponses EULAR, ASDAS, ASAS, ACR et PsARC) ont été évaluées avant et après l’infection par le SARS-Cov-2. Résultats Au total, 102 patients atteints de RP ont été inclus. Cinquante-deux étaient des femmes (51 %). L’âge moyen était de 53 ± 11,09 ans et la durée médiane de la maladie était de 15 ans [min 2, max 47]. Au total, 54 (53 %) patients avaient une atteinte axiale prédominante, 26 (26 %) périphérique et 36 (37 %) enthésopathique. Le bDMARD le plus utilisé était l’étanercept (n = 28, 27,5 %) suivi de l’adalimumab (n = 22, 21,6 %) et du sécukinumab (n = 18, 17,6 %). La prévalence de l’infection par le SARS-CoV-2 était de 15,7 % (n = 16). Soixante-trois pour cent ont reçu le vaccin BNT162b2 (Pfizer/BioNtech), 31 % ont reçu l’ARNm-1273 (Moderna), 13 % ont reçu l’AZD1222 (AstraZeneca) et 13 % ont reçu l’AD26.COV2.S (Janssen/Johnson & Johnson). Soixante-trois pour cent étaient infectés avant toute vaccination, 13 % après la première dose et 25 % après la seconde. Les symptômes les plus fréquents étaient l’anosmie (65 %), la dysgueusie (56 %) et la toux (56 %). Tous les patients se sont complètement remis de l’infection, sans nécessiter d’hospitalisation. Quel que soit le score utilisé, la différence entre l’activité moyenne de la maladie après l’infection par le SARS-CoV-2 et celle au départ n’a pas atteint la signification statistique. Au départ et après l’infection, les paramètres moyens de l’activité de la maladie étaient respectivement : CDAI 8,6 ± 5,7 vs 8,6 ± 5,7, p = 0,997 ; SDAI 9,3 ± 6,6 contre 9,2 ± 6,1, p = 0,928 ; DAS 28 4v 2,9 ± 1,2 contre 2,9 ± 1,2, p = 0,818 ; BASDAI 3,6 ± 2,6 contre 3,2 ± 2,7, p = 0,506 ; ASDAS 2,2 ± 1,2 contre 2,2 ± 1, p = 0,721. Le nombre de patients ne répondant pas aux bDMARD (selon EULAR, ASDAS, ASAS, ACR et PsARC) avant l’infection n’était pas différent de celui post-infection. Conclusion Notre étude suggère que l’infection par le SARS-CoV-2 n’a aucun impact négatif sur l’activité de la maladie PSA et les réponses bDMARD. Cependant, d’autres études sont encore nécessaires pour mieux comprendre les effets à long terme de l’infection par le SARS-CoV-2.
Collapse
Affiliation(s)
- R. Nicolau
- Rhumatologie, Centro Hospitalar Tondela – Viseu, Epe, Viseu, Portugal,Auteur correspondant
| | - A. Martins
- Rhumatologie, Centro Hospitalar Universitário de São-João, Porto, Portugal
| | - D. Oliveira
- Rhumatologie, Centro Hospitalar Universitário de São-João, Porto, Portugal
| | - B. Samões
- Département de rhumatologie, Centro Hospitalar Vila Nova de Gaia e Espinho, Vila Nova de Gaia
| | - F. Martins
- Rhumatologie, Centro Hospitalar Universitário do Algarve, Algarve, Portugal
| | - F. Pinheiro
- Rhumatologie, Centro Hospitalar e Universitário de São-João, Porto, Portugal
| | - M. Rato
- Rhumatologie, Centro Hospitalar e Universitário de São-João, Porto, Portugal
| | - M. Bernardes
- Rhumatologie, Centro Hospitalar São-João, Porto, Portugal
| | - L. Costa
- Rhumatologie, Centro Hospitalar De São-João, E.P.E., Porto, Portugal
| |
Collapse
|
9
|
Miranda M, Sandul A, Fernandes M, Lopes F, Castro A, Oliveira P, Leitão T, Martins F, Palma Reis J. McAninch penile circular skin flap urethroplasty: Do skin flaps still have a role in complex urethral strictures? EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02079-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
10
|
Verla W, Barratt R, Chan G, Campos-Juanatey F, Esperto F, Greenwell T, Lumen N, Martins F, Osman N, Ploumidis A, Riechardt S, Waterloos M, Dimitropoulos K. Is a course of Intermittent Self-Dilatation (ISD) with topical corticosteroids superior at stabilising urethral stricture disease in men and improving functional outcomes over a course of ISD alone? A systematic review and meta-analysis. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02051-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
11
|
Londral A, Azevedo S, Dias P, Ramos C, Santos J, Martins F, Silva R, Semedo H, Vital C, Gualdino A, Falcão J, Lapão LV, Coelho P, Fragata JG. Developing and validating high-value patient digital follow-up services: a pilot study in cardiac surgery. BMC Health Serv Res 2022; 22:680. [PMID: 35597936 PMCID: PMC9123610 DOI: 10.1186/s12913-022-08073-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 05/06/2022] [Indexed: 11/22/2022] Open
Abstract
Background The existing digital healthcare solutions demand a service development approach that assesses needs, experience, and outcomes, to develop high-value digital healthcare services. The objective of this study was to develop a digital transformation of the patients’ follow-up service after cardiac surgery, based on a remote patient monitoring service that would respond to the real context challenges. Methods The study followed the Design Science Research methodology framework and incorporated concepts from the Lean startup method to start designing a minimal viable product (MVP) from the available resources. The service was implemented in a pilot study with 29 patients in 4 iterative develop-test-learn cycles, with the engagement of developers, researchers, clinical teams, and patients. Results Patients reported outcomes daily for 30 days after surgery through Internet-of-Things (IoT) devices and a mobile app. The service’s evaluation considered experience, feasibility, and effectiveness. It generated high satisfaction and high adherence among users, fewer readmissions, with an average of 7 ± 4.5 clinical actions per patient, primarily due to abnormal systolic blood pressure or wound-related issues. Conclusions We propose a 6-step methodology to design and validate a high-value digital health care service based on collaborative learning, real-time development, iterative testing, and value assessment.
Collapse
Affiliation(s)
- A Londral
- Value for Health CoLAB, Lisbon, Portugal. .,Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.
| | - S Azevedo
- Value for Health CoLAB, Lisbon, Portugal.,Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.,CEG-IST, Instituto Superior Técnico, University of Lisbon, Lisbon, Portugal
| | - P Dias
- Value for Health CoLAB, Lisbon, Portugal.,Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - C Ramos
- Value for Health CoLAB, Lisbon, Portugal.,Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - J Santos
- Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.,Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - F Martins
- Value for Health CoLAB, Lisbon, Portugal.,NOVA-LINCS, NOVA School of Science and Technology, Nova University of Lisbon, Lisbon, Portugal
| | - R Silva
- Value for Health CoLAB, Lisbon, Portugal.,NOVA CLUNL - Center of Linguistics, Nova University of Lisbon, Lisbon, Portugal
| | - H Semedo
- Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - C Vital
- Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - A Gualdino
- Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - J Falcão
- Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - L V Lapão
- Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.,UNIDEMI, NOVA School of Science and Technology, Nova University of Lisboa, Lisbon, Portugal
| | - P Coelho
- Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.,Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| | - J G Fragata
- Comprehensive Health Research Center, Nova Medical School, Nova University of Lisbon, Lisbon, Portugal.,Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
| |
Collapse
|
12
|
Rodrigues S, Pinto I, Martins F, Formigo N, Antunes SC. Can biochemical endpoints improve the sensitivity of the biomonitoring strategy using bioassays with standard species, for water quality evaluation? Ecotoxicol Environ Saf 2021; 215:112151. [PMID: 33743402 DOI: 10.1016/j.ecoenv.2021.112151] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 03/08/2021] [Accepted: 03/11/2021] [Indexed: 06/12/2023]
Abstract
The Water Framework Directive (WFD) was adopted in 2000 and is a common framework for water policy, management and protection in Europe. The WFD assesses specific parameters; however, it ignores indicators of ecosystem functioning and sub-individual performance. Reservoirs are strongly influenced by anthropogenic activities that promote their imbalance. Bioassays and biomarkers are useful tools to link the chemical, ecological and toxicological assessments in water quality assessments. These approaches can be complementary to WFD methodologies, allowing the detection of impacts on the ecosystem. This study evaluated if the biochemical parameters can improve the sensitivity of the biomonitoring strategy using bioassays with the standard species Daphnia magna, in the assessment of the ecological quality of water reservoirs. To this end, water samples of Portuguese reservoirs were analysed in three sampling periods (Autumn 2018 and Spring, Autumn 2019). In parallel, a physicochemical characterization of waters was performed. D. magna feeding rate assays were performed for 24 h. After exposure, metabolism, oxidative stress and lipid peroxidation biomarkers were evaluated. Feeding rate assays showed sensitivity to different reservoirs. Biomarkers showed a higher sensitivity and can therefore improve the sensitivity of the biomonitoring strategy using bioassays. Bioassays and biomarkers approach allowed to highlight potential sources of stress, more related to the quality of the seston than to chemical contamination. This work highlights the complementarity between bioassays and biomarkers to identify ecotoxicological effects of surface waters, and can be extremely useful, especially in cases where the biotic indices are difficult to establish, such as reservoirs.
Collapse
Affiliation(s)
- S Rodrigues
- Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal; CIMAR/CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Matosinhos, Portugal.
| | - I Pinto
- Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal; CIMAR/CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Matosinhos, Portugal
| | - F Martins
- Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal; CIMAR/CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Matosinhos, Portugal
| | - N Formigo
- Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal
| | - S C Antunes
- Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal; CIMAR/CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Matosinhos, Portugal
| |
Collapse
|
13
|
Blondon M, Jimenez D, Robert‐Ebadi H, Del Toro J, Lopez‐Jimenez L, Falga C, Skride A, Font L, Vazquez FJ, Bounameaux H, Monreal M, Prandoni P, Brenner, B, Farge‐Bancel D, Barba R, Di Micco P, Bertoletti L, Schellong S, Tzoran I, Reis A, Bosevski M, Malý R, Verhamme P, Caprini JA, My Bui H, Adarraga MD, Agud M, Aibar J, Aibar MA, Alfonso J, Amado C, Arcelus JI, Baeza C, Ballaz A, Barba R, Barbagelata C, Barrón M, Barrón‐Andrés B, Blanco‐Molina A, Botella E, Camon AM, Castro J, Caudevilla MA, Cerdà P, Chasco L, Criado J, de Ancos C, de Miguel J, Demelo‐Rodríguez P, Díaz‐Peromingo JA, Díez‐Sierra J, Díaz‐Simón R, Domínguez IM, Encabo M, Escribano JC, Falgá C, Farfán AI, Fernández‐Capitán C, Fernández‐Reyes JL, Fidalgo MA, Flores K, Font C, Francisco I, Gabara C, Galeano‐Valle F, García MA, García‐Bragado F, García‐Mullor MM, Gavín‐Blanco O, Gavín‐Sebastián O, Gil‐Díaz A, Gómez‐Cuervo C, González‐Martínez J, Grau E, Guirado L, Gutiérrez J, Hernández‐Blasco L, Jara‐Palomares L, Jaras MJ, Jiménez D, Joya MD, Jou I, Lacruz B, Lecumberri R, Lima J, Lobo JL, López‐Brull H, López‐Jiménez L, López‐Miguel P, López‐Núñez JJ, López‐Reyes R, López‐Sáez JB, Lorente MA, Lorenzo A, Loring M, Madridano O, Maestre A, Marchena PJ, Martín del Pozo M, Martín‐Martos F, Martínez‐Baquerizo C, Mella C, Mellado M, Mercado MI, Moisés J, Morales MV, Muñoz‐Blanco A, Muñoz‐Guglielmetti D, Muñoz‐Rivas N, Nart E, Nieto JA, Núñez MJ, Olivares MC, Ortega‐Michel C, Ortega‐Recio MD, Osorio J, Otalora S, Otero R, Parra P, Parra V, Pedrajas JM, Pellejero G, Pérez‐Jacoiste A, Peris ML, Pesántez D, Porras JA, Portillo J, Reig L, Riera‐Mestre A, Rivas A, Rodríguez‐Cobo A, Rodríguez‐Matute C, Rogado J, Rosa V, Rubio CM, Ruiz‐Artacho P, Ruiz‐Giménez N, Ruiz‐Ruiz J, Ruiz‐Sada P, Sahuquillo JC, Salgueiro G, Sampériz A, Sánchez‐Muñoz‐Torrero JF, Sancho T, Sigüenza P, Sirisi M, Soler S, Suárez S, Suriñach JM, Tiberio G, Torres MI, Tolosa C, Trujillo‐Santos J, Uresandi F, Usandizaga E, Valle R, Vela JR, Vidal G, Vilar C, Villares P, Zamora C, Gutiérrez P, Vázquez FJ, Vanassche T, Vandenbriele C, Verhamme P, Hirmerova J, Malý R, Salgado E, Benzidia I, Bertoletti L, Bura‐Riviere A, Crichi B, Debourdeau P, Espitia O, Farge‐Bancel D, Helfer H, Mahé I, Moustafa F, Poenou G, Schellong S, Braester A, Brenner B, Tzoran I, Amitrano M, Bilora F, Bortoluzzi C, Brandolin B, Ciammaichella M, Colaizzo D, Dentali F, Di Micco P, Giammarino E, Grandone E, Mangiacapra S, Mastroiacovo D, Maida R, Mumoli N, Pace F, Pesavento R, Pomero F, Prandoni P, Quintavalla R, Rocci A, Siniscalchi C, Tufano A, Visonà A, Vo Hong N, Zalunardo B, Kalejs RV, Maķe K, Ferreira M, Fonseca S, Martins F, Meireles J, Bosevski M, Zdraveska M, Mazzolai L, Caprini JA, Tafur AJ, Weinberg I, Wilkins H, Bui HM. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. J Thromb Haemost 2021; 19:408-416. [PMID: 33119949 DOI: 10.1111/jth.15146] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 09/29/2020] [Accepted: 10/21/2020] [Indexed: 01/16/2023]
Abstract
AIMS Little is known about the prognosis of patients with massive pulmonary embolism (PE) and its risk of recurrent venous thromboembolism (VTE) compared with non-massive PE, which may inform clinical decisions. Our aim was to compare the risk of recurrent VTE, bleeding, and mortality after massive and non-massive PE during anticoagulation and after its discontinuation. METHODS AND RESULTS We included all participants in the RIETE registry who suffered a symptomatic, objectively confirmed segmental or more central PE. Massive PE was defined by a systolic hypotension at clinical presentation (<90 mm Hg). We compared the risks of recurrent VTE, major bleeding, and mortality using time-to-event multivariable competing risk modeling. There were 3.5% of massive PE among 38 996 patients with PE. During the anticoagulation period, massive PE was associated with a greater risk of major bleeding (subhazard ratio [sHR] 1.72, 95% confidence interval [CI] 1.28-2.32), but not of recurrent VTE (sHR 1.15, 95% CI 0.75-1.74) than non-massive PE. An increased risk of mortality was only observed in the first month after PE. After discontinuation of anticoagulation, among 11 579 patients, massive PE and non-massive PE had similar risks of mortality, bleeding, and recurrent VTE (sHR 0.85, 95% CI 0.51-1.40), but with different case fatality of recurrent PE (11.1% versus 2.4%, P = .03) and possibly different risk of recurrent fatal PE (sHR 3.65, 95% CI 0.82-16.24). CONCLUSION In this large prospective registry, the baseline hemodynamic status of the incident PE did not influence the risk of recurrent VTE, during and after the anticoagulation periods, but was possibly associated with recurrent PE of greater severity.
Collapse
Affiliation(s)
- Marc Blondon
- Division of Angiology and Hemostasis Geneva University Hospitals and Faculty of Medicine Geneva Switzerland
| | - David Jimenez
- Respiratory Department Hospital Ramón y Cajal and Medicine Department Universidad de Alcalá (IRYCIS) Madrid Spain
| | - Helia Robert‐Ebadi
- Division of Angiology and Hemostasis Geneva University Hospitals and Faculty of Medicine Geneva Switzerland
| | - Jorge Del Toro
- Department of Internal Medicine Hospital General Universitario Gregorio Marañón Madrid Spain
| | | | - Conxita Falga
- Department of Internal Medicine Hospital de Mataro Barcelona Spain
| | - Andris Skride
- Department of Cardiology Ospedale Pauls Stradins Clinical University Hospital Riga Latvia
| | - Llorenç Font
- Department of Haematology Hospital de Tortosa Verge de la Cinta Tarragona Spain
| | | | - Henri Bounameaux
- Division of Angiology and Hemostasis Geneva University Hospitals and Faculty of Medicine Geneva Switzerland
| | - Manuel Monreal
- Department of Internal Medicine Hospital Germans Trias i Pujol Badalona Spain
- Universidad Catolica de Murcia Murcia Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Shiraishi R, Bombeiro A, Castro T, Martins F, Via F, Santos I, Rego E, Queiroz M, Torello C, Saad S. IMAGEAMENTO IN VIVO DE CAMUNDONGOS TRANSPLANTADOS COM LEUCEMIA PROMIELOCÍTICA AGUDA (PML-RARα). Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Martins F, Kruszewski M, Scarpelli I, Schoumans J, Spertini O, Lübbert M, Blum S. Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. Ann Hematol 2020; 100:63-78. [PMID: 32556451 DOI: 10.1007/s00277-020-04114-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Accepted: 06/01/2020] [Indexed: 12/17/2022]
Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases, with a variable probability of transformation into acute leukemia, which is, in the vast majority of cases, of myeloid lineage. Nevertheless, rare cases of acute lymphoblastic leukemia in patients with previously diagnosed MDS have been reported. We describe a series of 3 cases of MDS/CMML marked with evolution to acute lymphoblastic leukemia (ALL) and provide a comprehensive review of the 49 cases documented in the literature so far. These sporadic events have only been published as single-case reports or small series to date. Such atypical cases emphasize the possibility of major phenotypic switches arising at the leukemic stem cell (LSC) and/or early progenitor levels, as a consequence of epigenetic and genomic events driving these changes in the bone marrow niche.
Collapse
Affiliation(s)
- Filipe Martins
- Centre Hospitalier Universitaire Vaudois (CHUV), Hematology Service and Central laboratory, Oncology department, Rue du Bugnon 46, Lausanne, CH-1011, Switzerland. .,Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland. .,School of Life Sciences, Laboratory of Virology and Genetics, Swiss Federal Institute of Technology Lausanne (EPFL), Station 19, CH-1015, Lausanne, Switzerland.
| | - Michael Kruszewski
- Internal Medicine 1, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Hospital Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
| | - Ilaria Scarpelli
- Oncogenomic Laboratory, Hematology Service, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland
| | - Jacqueline Schoumans
- Oncogenomic Laboratory, Hematology Service, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland
| | - Olivier Spertini
- Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland.,Oncogenomic Laboratory, Hematology Service, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland
| | - Michael Lübbert
- Internal Medicine 1, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Hospital Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
| | - Sabine Blum
- Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland.
| |
Collapse
|
16
|
Felicio J, Pé-Leve P, Castro A, Gomes J, Martins N, Lopes T, Martins F. P-02-28 A Minimally Invasive Procedure in the Surgical Treatment of Peyronie's Disease: Short- and Mid-Term Results. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2020.04.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 2020; 20:e54-e64. [PMID: 30614479 DOI: 10.1016/s1470-2045(18)30828-3] [Citation(s) in RCA: 128] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 10/09/2018] [Accepted: 10/30/2018] [Indexed: 12/14/2022]
Abstract
Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxicities for healthcare practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of patients with cancer are increasingly confronted with the therapeutic challenge of treating patients with severe and refractory immune-related adverse events. In this Personal View, we summarise the therapeutic strategies that have been used to manage such toxicities resulting from immune checkpoint inhibitor treatment. On the basis of current knowledge about their pathogenesis, we discuss the use of new biological and non-biological immunosuppressive drugs to treat severe and steroid refractory immune-related adverse events. Depending on the immune infiltrate type that is predominant, we propose a treatment algorithm for personalised management that goes beyond typical corticosteroid use. We propose a so-called shut-off strategy that aims at inhibiting key inflammatory components involved in the pathophysiological processes of immune-related adverse events, and limits potential adverse effects of drug immunosuppression on tumour response. This approach develops on current guidelines and challenges the step-by-step increase approach to drug immunosuppression.
Collapse
Affiliation(s)
- Filipe Martins
- Département d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Gerasimos P Sykiotis
- Service d'Endocrinologie, Diabétologie, et Métabolisme, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Michel Maillard
- Service de Gastro-entérologie et Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Crohn's and Colitis Center, Lausanne, Switzerland
| | - Montserrat Fraga
- Service de Gastro-entérologie et Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Camillo Ribi
- Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Thierry Kuntzer
- Service de Neurologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Olivier Michielin
- Département d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Solange Peters
- Département d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Georges Coukos
- Département d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Epalinges, Switzerland
| | - Francois Spertini
- Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - John A Thompson
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA; National Cancer Institute, Bethesda, MA, USA
| | - Michel Obeid
- Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Centre d'Immunothérapie et de Vaccinologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculté Médecine Paris Descartes, Université Paris Descartes, Paris, France.
| |
Collapse
|
18
|
Sargsyan L, Martins F. Evaluation of a new visualization and analytics solution for slow control data for large scale experiments. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202024507001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Large experiments in high energy physics require efficient and scalable monitoring solutions to digest data of the detector control system. Plotting multiple graphs in the slow control system and extracting historical data for long time periods are resource intensive tasks. The proposed solution leverages the new virtualization, data analytics and visualization technologies such as InfluxDB time-series database for faster access large scale data, Grafana to visualize time-series data and an OpenShift container platform to automate build, deployment, and management of application. The monitoring service runs separately from the control system thus reduces a workload on the control system computing resources. As an example, a test version of the new monitoring was applied to the ATLAS Tile Calorimeter using the CERN Cloud Process as a Service platform. Many dashboards in Grafana have been created to monitor and analyse behaviour of the High Voltage distribution system. They visualize not only values measured by the control system, but also run information and analytics data (difference, deviation, etc.). The new monitoring with a feature-rich visualization, filtering possibilities and analytics tools allows to extend detector control and monitoring capabilities and can help experts working on large scale experiments.
Collapse
|
19
|
Nobre F, Muniz R, Martins F, Silva B, de Matos J, da Silva E, Couceiro P, Brito W, Leyet Y. Calcium molybdate: Toxicity and genotoxicity assay in Drosophila melanogaster by SMART test. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2019.127096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
20
|
Garcia Bras P, Aguiar Rosa S, Ferreira L, Moura Branco L, Castelo A, Vaz Ferreira V, Branco Ferrao J, Martins F, Sousa L, Fiarresga A, Pinto E, Ferreira RC. P229 Primary cardiac angiosarcoma of the right atrium: a rare entity presenting with an atrial arrhythmia. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Primary cardiac tumors are rare entities and 75% are benign. Angiosarcoma is the most common malignant primary cardiac tumor.
We report the case of cardiac angiosarcoma presenting with an atrial arrhythmia.
Clinical case
A 39-year-old female patient with no past medical history presented to the emergency department with heart palpitations and atypical chest pain.
Electrocardiogram on admission showed atrial flutter with a heart rate of 153 beats per minute.
Laboratory analysis were performed showing elevated D-dimer levels (2210 ug/L).
A thoracic CT scan was performed, which ruled out pulmonary embolism, but showed multiple pulmonary nodules and a right atrial (RA) mass measuring 48 mm that could correspond to a thrombus or neoplasia.
The patient was admitted in the Cardiology ICU of our hospital and was started on beta-blocker and amiodarone with conversion to sinus rhythm. Additional exams were performed:
- Transthoracic echocardiogram (TTE) revealed an heterogenous 32,6 x 17,7 mm mass in the lateral wall of the RA with an adherent mobile mass near the tricuspid valve with 28 mm diameter (possible adherent thrombus).
- Cardiac magnetic resonance imaging confirmed a RA tumor with invasion of the atrial free wall and compression of the superior vena cava.
Due to the unclear etiology of the RA mass, ultrasound-guided intracardiac biopsy was performed. Pathological examination revealed spindle cell proliferation, consistent with the diagnosis of angiosarcoma. Immunohistochemical staining was positive for Vimentin, CD34 and CD31, with 70% Ki67 expression.
Later on, the patient developed melena with significant drop of hemoglobin levels, requiring daily red blood cell transfusions and anticoagulation had to be stopped.
The patient was transferred to the Internal Medicine ward and thoracic-abdomen-pelvis staging computed tomography (CT) scan showed a significant increase in the number of pulmonary nodules, bilateral ovarian masses, 4 hepatic nodules and ileum metastization.
During hospitalization, the patient developed right leg deep venous thrombosis and thoracic CT scan revealed bilateral pulmonary embolism.
After improvement of the clinical status, palliative chemotherapy was started and the patient was discharged, maintaining regular outpatient follow-up in the Oncology Department for 1 month.
Cardiac angiosarcoma generally presents in a late stage of the disease with metastatic involvement. When surgical treatment is not possible, despite agressive chemotherapy, the prognosis remains poor.
Abstract P229 Figure. Echocardiogram: right atrium mass
Collapse
Affiliation(s)
| | | | - L Ferreira
- Hospital de Santa Marta, Lisbon, Portugal
| | | | - A Castelo
- Hospital de Santa Marta, Lisbon, Portugal
| | | | | | - F Martins
- Hospital dos Capuchos, Lisbon, Portugal
| | - L Sousa
- Hospital de Santa Marta, Lisbon, Portugal
| | | | - E Pinto
- Hospital de Santa Marta, Lisbon, Portugal
| | | |
Collapse
|
21
|
Mendes N, Dias Carvalho P, Martins F, Mendonça S, Malheiro AR, Ribeiro A, Carvalho J, Velho S. Animal Models to Study Cancer and Its Microenvironment. Adv Exp Med Biol 2020; 1219:389-401. [PMID: 32130710 DOI: 10.1007/978-3-030-34025-4_20] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Cancers are complex tissues composed by genetically altered cancer cells and stromal elements such as inflammatory/immune cells, fibroblasts, endothelial cells and pericytes, neuronal cells, and a non-cellular component, the extracellular matrix. The complex network of interactions and crosstalk established between cancer cells and the supportig cellular and non-cellular components of the microenvironment are of extreme importance for tumor initiation and progression, strongly impacting the course and the outcome of the disease. Therefore, a better understanding of the tumorigenic processes implies the combined study of the cancer cell and the biologic, chemical and mechanic constituents of the tumor microenvironment, as their concerted action plays a major role in the carcinogenic pathway and is a key determinant of the efficacy of anti-cancer treatments. The use of animal models (e.g. Mouse, Zebrafish and Drosophila) to study cancer has greatly impacted our understanding of the processes governing initiation, progression and metastasis and allowed the discovery and pre-clinical validation of novel cancer treatments as it allows to recreate tumor development in a more pathophysiologic environment.
Collapse
Affiliation(s)
- N Mendes
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal.
| | - P Dias Carvalho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - F Martins
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - S Mendonça
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - A R Malheiro
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IBMC, Instituto de Biologia Molecular e Celular da Universidade do Porto, Porto, Portugal
| | - A Ribeiro
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - J Carvalho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - S Velho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal.
| |
Collapse
|
22
|
Azevedo S, Guimarães F, Leite Silva J, Barros R, Capela S, Abreu P, Cunha Miranda L, Dourado E, Faustino A, Ferreira J, Las V, Martins F, Martins Rocha T, Meirinhos T, Salvador MJ, Santos-Faria D, Soares Rodrigues M, Teixeira F, Cunha I. The role of opioid analgesics in rheumatic disorders: a position paper from the Portuguese Rheumatology Society. Acta Reumatol Port 2020; 45:7-19. [PMID: 32572015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Pain is a common feature of most rheumatic diseases and it is often the main reason for the patient to seek for a clinical appointment. Chronic pain has a major impact on patient's quality of life, being frequently associated with functional incapacity, sleep and mood disorders. This leads to absenteeism and heavy consumption of health resources, both representing huge burdens on national economy. Managing musculoskeletal pain is pivotal but can be challenging. The use of the available pharmaceutical armamentarium should be parsimonious. Opioids are strong analgesic drugs that mostly act through their agonist action on µ-receptors in the central nervous system. Opioid-related side effects are not negligible and are mediated through both central and peripheral opioid receptors. The use of opioids is well established in the treatment of oncologic pain but their role in the management of musculoskeletal pain is still controversial. Inflammatory rheumatic diseases, osteoarthritis, osteoporotic fractures, chronic low back pain and fibromyalgia represent diverse major rheumatic conditions that frequently lead to chronic pain. In order to standardize and optimize management of musculoskeletal chronic pain in these prevalent diseases, the Portuguese Rheumatology Society elaborated this position paper. The objectives were: a) to define the importance of pain assessment and classification; b) to guide patient selection, appropriate choice of opioids, their management, and raise awareness of their adverse effects; c) to review the existent data on possible indications of opioid therapy on rheumatic diseases.
Collapse
|
23
|
Mendes N, Dias Carvalho P, Martins F, Mendonça S, Malheiro AR, Ribeiro A, Carvalho J, Velho S. Correction to: Animal Models to Study Cancer and Its Microenvironment. Adv Exp Med Biol 2020; 1219:C1. [PMID: 38379237 DOI: 10.1007/978-3-030-34025-4_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Affiliation(s)
- N Mendes
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal.
| | - P Dias Carvalho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - F Martins
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - S Mendonça
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - A R Malheiro
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IBMC, Instituto de Biologia Molecular e Celular da Universidade do Porto, Porto, Portugal
| | - A Ribeiro
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - J Carvalho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal
| | - S Velho
- i3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
- IPATIMUP, Instituto de Patologia Molecular e Imunologia da Universidade do Porto, Porto, Portugal.
| |
Collapse
|
24
|
Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet MA, Aedo-Lopez V, Gautron Moura B, Homicsko K, Bettini A, Berthod G, Gérard CL, Wicky A, Bourhis J, Michielin O. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. J Neurooncol 2019; 146:181-193. [PMID: 31836957 DOI: 10.1007/s11060-019-03363-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Accepted: 12/09/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze the effect on overall survival (OS) of immune checkpoint inhibitors (ICI) or BRAF/MEK inhibitors initiated during the 9 weeks before or after SRS. We also evaluated the prognostic value of patients' and disease characteristics as predictors of OS in patients treated with SRS. METHODS We identified patients with BM from cutaneous or unknown primary origin melanoma treated with SRS between 2011 and 2018. RESULTS We included 84 patients. The median OS was 12 months (95% CI 9-20 months). The median follow-up was 30 months (95% CI 28-49). Twenty-eight patients with newly diagnosed BM initiated anti-PD-1 +/-CTLA-4 therapy (n = 18), ipilimumab monotherapy (n = 10) or BRAF+/- MEK inhibitors (n = 11), during the 9 weeks before or after SRS. Patients who received anti-PD-1 +/-CTLA-4 mAb showed an improved survival in comparison to ipilimumab monotherapy (OS 24 vs. 7.5 months; HR 0.32, 95% 0.12-0.83, p = 0.02) and BRAF +/-MEK inhibitors (OS 24 vs. 7 months, respectively; HR 0.11, 95% 0.04-0.34, p = 0.0001). This benefit remained significant when compared to the subgroup of patients treated with dual BRAF/MEK inhibition (BMi) (n = 5). In a multivariate Cox regression analysis an age > 65, synchronous BM, > 2 metastatic sites, > 4 BM, and an ECOG > 1 were correlated with poorer prognosis. A treatment with anti-PD-1+/-CTLA-4 mAbs within 9 weeks of SRS was associated with better outcomes. The presence of serum lactate dehydrogenase (LDH) levels ≥ 2xULN at BM diagnosis was associated with lower OS (HR 1.60, 95% CI 1.03-2.50; p = 0.04). CONCLUSIONS The concurrent administration of anti-PD-1+/-CTLA-4 mAbs with SRS was associated with improved survival in melanoma patients with newly diagnosed BM. In addition to CNS tumor burden, the extension of systemic disease retains its prognostic value in patients treated with SRS. Elevated serum LDH levels are predictors of poor outcome in these patients.
Collapse
Affiliation(s)
- Filipe Martins
- Centre Hospitalier Universitaire Vaudois (CHUV), Hematology Service and Central Laboratory, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
- Swiss Federal Institute of Technology Lausanne (Ecole polytechnique Fédérale de Lausanne, EPFL), School of Life Sciences, Laboratory of Virology and Genetics (LVG), EPFL-SV-GHI-LVG, Station 11, CH-1015, Lausanne, Switzerland.
| | - Luis Schiappacasse
- Centre Hospitalier Universitaire Vaudois (CHUV), Radio-Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Marc Levivier
- Centre Hospitalier Universitaire Vaudois (CHUV), Neurosurgery Service and Gamma Knife Center, Clinical Neurosciences Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Constantin Tuleasca
- Centre Hospitalier Universitaire Vaudois (CHUV), Neurosurgery Service and Gamma Knife Center, Clinical Neurosciences Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
- Swiss Federal Institute of Technology Lausanne (Ecole polytechnique Fédérale de Lausanne, EPFL), Signal Processing Laboratory (LTS5), EPFL-STI-IEL-LTS5, Station 11, CH-1015, Lausanne, Switzerland
- University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Rue du Bugnon 21, CH-1005, Lausanne, Switzerland
| | - Michel A Cuendet
- Centre Hospitalier Universitaire Vaudois (CHUV), Precision Oncology Center, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
- Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA
| | - Veronica Aedo-Lopez
- Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Bianca Gautron Moura
- Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Krisztian Homicsko
- Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Adrienne Bettini
- Fribourg Cantonal Hospital (HFR), Internal Medicine Department, Oncology Service, CH-1708, Fribourg, Switzerland
| | - Gregoire Berthod
- Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
- Hospital Center for Valais Romand (CHVR), Martigny Hospital, Avenue de la Fusion 27, CH-1920, Martigny, Switzerland
| | - Camille L Gérard
- Centre Hospitalier Universitaire Vaudois (CHUV), Precision Oncology Center, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Alexandre Wicky
- Centre Hospitalier Universitaire Vaudois (CHUV), Precision Oncology Center, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Jean Bourhis
- Centre Hospitalier Universitaire Vaudois (CHUV), Radio-Oncology Service, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
| | - Olivier Michielin
- Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Precision Oncology Center, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
| |
Collapse
|
25
|
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16:563-580. [PMID: 31092901 DOI: 10.1038/s41571-019-0218-0] [Citation(s) in RCA: 1078] [Impact Index Per Article: 215.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.
Collapse
Affiliation(s)
- Filipe Martins
- Service et Laboratoire Central d'Hématologie, Département d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.,School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | | | - Gerasimos P Sykiotis
- Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV, Lausanne, Switzerland
| | - Faiza Lamine
- Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV, Lausanne, Switzerland
| | - Michel Maillard
- Service de Gastro-entérologie et Hépatologie, CHUV, Lausanne, Switzerland.,Crohn's and Colitis Center Lausanne, Lausanne, Switzerland
| | - Montserrat Fraga
- Service de Gastro-entérologie et Hépatologie, CHUV, Lausanne, Switzerland
| | | | - Camillo Ribi
- Service Immunologie et Allergie, CHUV, Lausanne, Switzerland
| | - Anne Cairoli
- Service et Laboratoire Central d'Hématologie, Département d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
| | - Yan Guex-Crosier
- Hôpital Ophtalmique Jules Gonin - Fondation Asile des Aveugles, CHUV, Lausanne, Switzerland
| | | | | | | | - Georges Coukos
- Département d'Oncologie, CHUV, Lausanne, Switzerland.,Ludwig Institute for Cancer Research, Epalinges, Switzerland
| | | | - John A Thompson
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,National Cancer Institute, NIH, Bethesda, MD, USA
| | - Michel Obeid
- Service Immunologie et Allergie, CHUV, Lausanne, Switzerland. .,Faculté de Médecine Pitié-Salpêtrière, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France. .,Centre d'Immunothérapie et de Vaccinologie, CHUV, Lausanne, Switzerland.
| |
Collapse
|
26
|
Afsar A, Martins F, Oliveira BMPM, Pinto AA. A fit of CD4 + T cell immune response to an infection by lymphocytic choriomeningitis virus. Math Biosci Eng 2019; 16:7009-7021. [PMID: 31698601 DOI: 10.3934/mbe.2019352] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
We fit an immune response model to data reporting the CD4+ T cell numbers from the 28 days following the infection of mice with lymphocytic choriomeningitis virus LCMV. We used an ODE model that was previously used to describe qualitatively the behaviour of CD4+ T cells, regulatory T cells (Tregs) and interleukine-2 (IL-2) density. The model considered two clonotypes of T cells in order to fit simultaneously the two time series for the gp61 and NP309 epitopes. We observed the proliferation of T cells and, to a lower extent, Tregs during the immune activation phase following infection and subsequently, during the contraction phase, a smooth transition from faster to slower death rates. The six parameters that were optimized were: the beginning and ending times of the immune response, the growth rate of T cells, their capacity, and the two related with the homeostatic numbers of T cells that respond to each epitope. We showed that the ODE model was able to be calibrated thus providing a quantitative description of the data.
Collapse
Affiliation(s)
- Atefeh Afsar
- Departamento de Matemática, Faculdade de Ciências da Universidade do Porto and LIAAD-INESC. Rua do Campo Alegre, 687, 4169-007 Porto, Portugal
| | - Filipe Martins
- Departamento de Matemática, Faculdade de Ciências da Universidade do Porto and LIAAD-INESC. Rua do Campo Alegre, 687, 4169-007 Porto, Portugal
| | - Bruno M P M Oliveira
- Faculdade de Ciências da Nutrição e Alimentação da Universidade do Porto, and LIAAD-INESC. Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Alberto A Pinto
- Departamento de Matemática, Faculdade de Ciências da Universidade do Porto and LIAAD-INESC. Rua do Campo Alegre, 687, 4169-007 Porto, Portugal
| |
Collapse
|
27
|
Voruz S, Martins F, Cairoli A, Naveiras O, Homicsko K, Missiaglia E, de Leval L, Bisig B, Michielin O, Blum S. Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma". Haematologica 2019; 103:e130. [PMID: 29491129 DOI: 10.3324/haematol.2017.186932] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Affiliation(s)
- Sophie Voruz
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | - Filipe Martins
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | - Anne Cairoli
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | - Olaia Naveiras
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | | | - Edoardo Missiaglia
- Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland
| | - Laurence de Leval
- Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland
| | - Bettina Bisig
- Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland
| | - Olivier Michielin
- Department of Oncology, University Hospital of Lausanne, Switzerland
| | - Sabine Blum
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| |
Collapse
|
28
|
Simoes de Oliveira P, Riberio de Oliveira T, Martinho D, Pereira e Silva R, Marcelino J, Reis JP, Martins F, Lopes T. 422 The impact of sacral neuromodulation on male erectile function. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Simoes de Oliveira P, Ribeiro de Oliveira T, Martins F, Lopes T. 288 The role of low-intensity shock wave therapy on erectile dysfunction. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Martins F, Stalder G, Obeid M. Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy. Neoplasia 2017; 20:193-196. [PMID: 29287248 PMCID: PMC5884002 DOI: 10.1016/j.neo.2017.11.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Revised: 11/16/2017] [Accepted: 11/20/2017] [Indexed: 12/22/2022] Open
Affiliation(s)
- Filipe Martins
- Centre hospitalier universitaire vaudois (CHUV), Service et laboratoire central d'hématologie, département d'oncologie, rue du Bugnon 46, CH-1011 Lausanne, Switzerland
| | - Grégoire Stalder
- Centre hospitalier universitaire vaudois (CHUV), Service et laboratoire central d'hématologie, département d'oncologie, rue du Bugnon 46, CH-1011 Lausanne, Switzerland
| | - Michel Obeid
- Centre hospitalier universitaire vaudois (CHUV), Centre d'immunothérapie et de la vaccinologie, rue du Bugnon 17, CH-1011 Lausanne, Switzerland; Université Pierre et Marie Curie, Faculté de Médecine Pitié-Salpêtrière, Centre Hospitalo-Universitaire Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, F-75013 Paris, France.
| |
Collapse
|
31
|
Martins F, Castro F, Pinto ML, Silva AJ, Sousa B, Oliveira MJ, Costa ÂM. The role of the hypoxic tumor microenvironment on the macrophage-tumor cell interplay: PS124. Porto Biomed J 2017; 2:216. [PMID: 32258710 DOI: 10.1016/j.pbj.2017.07.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- F Martins
- Department of Biology, Faculty of Sciences, UPorto, Porto, Portugal.,i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal
| | - F Castro
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal.,ICBAS- Instituto de Ciências Biomédicas Abel Salazar, UPorto, Porto, Portugal
| | - M L Pinto
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal.,ICBAS- Instituto de Ciências Biomédicas Abel Salazar, UPorto, Porto, Portugal
| | - A J Silva
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal
| | - B Sousa
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,IPATIMUP- Institute of Molecular Pathology and Immunology of the University of Porto, Portugal
| | - M J Oliveira
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal.,Department of Pathology and Oncology, Faculty of Medicine, UPorto, Porto, Portugal
| | - Â M Costa
- i3S - Instituto de Investigação e Inovação em Saúde, UPorto, Porto, Portugal.,INEB - Institute of Biomedical Engineering, UPorto, Portugal
| |
Collapse
|
32
|
Abstract
The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some improvement has been made for acute lymphoblastic leukemia (ALL). Emerging new treatment modalities, such as immunotherapy, are now beginning to be available for acute leukemia, mostly for patients suffering from ALL. This review aims to give an overview of these new therapeutic approaches, especially those already available. The focus is on cell-based immunotherapy, or molecules using preexisting host cells. Underlying mechanisms are explained and an overview of clinical experience with phase 1-3 studies is given. Immunotherapies discussed are antibody-drug conjugates, bispecific T-cell engagers (BiTEs), chimeric antigen receptor T cells (CARTs) and immune checkpoint inhibitors (ICPIs). Most of the clinical studies reviewed are in ALL patients, usually in the relapse setting, but where available, studies on AML patients were also considered. This new general treatment approach offers hope to patients with until now dismal clinical outcome. Hopes are high that future developments, and moving these therapies to an earlier treatment phase, will improve the prognosis of patients suffering from acute leukemia.
Collapse
Affiliation(s)
- Sabine Blum
- Service and Central Laboratory of Hematology, Oncology Department, CHUV, University Hospital Lausanne, Lausanne, Switzerland.
| | - Filipe Martins
- Service and Central Laboratory of Hematology, Oncology Department, CHUV, University Hospital Lausanne, Lausanne, Switzerland
| | - Michael Lübbert
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany
| |
Collapse
|
33
|
Pragosa H, Marçal M, Gonçalves E, Martins F, Lopo-Tuna M. Multi-drug-resistant Enterobacteriaceae in a Portuguese neonatal intensive care unit. J Hosp Infect 2017; 96:130-131. [PMID: 28433397 DOI: 10.1016/j.jhin.2017.03.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 03/13/2017] [Indexed: 11/25/2022]
Affiliation(s)
- H Pragosa
- Hospital de Sao Francisco Xavier, Lisboa, Portugal.
| | - M Marçal
- Unidade de Neonatologia, Serviço de Pediatria, Hospital de São Francisco Xavier, Lisboa, Portugal
| | - E Gonçalves
- Serviço de Patologia Clínica, Laboratório de Microbiologia, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal
| | - F Martins
- Coordenadora do Grupo de Coordenação local do Programa de Prevenção e Controlo da Infecção e Resistência aos Antimicrobianos, Centro Hospitalar de Lisboa Ocidental, Portugal
| | - M Lopo-Tuna
- Coordenadora da Unidade de Neonatologia, Serviço de Pediatria, Hospital de São Francisco Xavier, Lisboa, Portugal
| |
Collapse
|
34
|
Angulo JC, Arance I, Esquinas C, Nikolavsky D, Martins N, Martins F. Treatment of long anterior urethral stricture associated to lichen sclerosus. Actas Urol Esp 2017; 41:123-131. [PMID: 27816211 DOI: 10.1016/j.acuro.2016.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2016] [Revised: 08/30/2016] [Accepted: 09/01/2016] [Indexed: 12/30/2022]
Abstract
INTRODUCTION Panurethral stricture associated with lichen sclerosus is a therapeutic challenge. We present the analysis of our results using two urethroplasty techniques based on oral mucosa graft. MATERIAL AND METHOD Retrospective study in patients with long anterior urethral stricture (>8cm) associated with lichen sclerosus. Patients received urethroplasty with oral mucosa graft technique according Kulkarni (n=25) or two-step Johanson-Bracka urethroplasty (n=15). Demographics, operative time, complications (Clavien-Dindo), hospital stay, days with catheter, EAV postoperative pain, failure rate, need for retreatment and functional data including IPSS, QoL, Qmax, post void residual (PVR) are evaluated. RESULTS In all cases there was involvement of glandular and penile urethra, and in 75% of bulbar urethra. A single graft was used in 22.5%, two in 72.5% and three in 5%. Patients treated at a single step were younger (P=.007). Although the length of the stenosis was equivalent in both techniques (P=.96), relapse and complication rates were higher in two-step surgery (P=.05 and P=.03; respectively) and so was operative time (P<.0001) and overall stay (P=.0002). There were no differences in preoperative IPSS, QoL, Qmax or PVR, neither in postoperative values of IPSS or Qmax; but there was a difference in QoL (P=.006) and PVR (P=.03) favouring single-step urethroplasty. VAS pain on postoperative day 1 was also lower in Kulkarni urethroplasty than in the first step of Johanson-Bracka technique (P<.0001). CONCLUSIONS In patients with lichen sclerosus and long anterior urethral stricture Kulkarni urethroplasty provides more efficient and better patient reported outcomes than Johanson-Bracka urethroplasty. It also prevents cosmetic, sexual and voiding temporary deterioration inherent to 2-step surgery.
Collapse
Affiliation(s)
- J C Angulo
- Departamento Clínico, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Laureate Universities, Madrid, España; Servicio de Urología, Hospital Universitario de Getafe, Madrid, España.
| | - I Arance
- Departamento Clínico, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Laureate Universities, Madrid, España
| | - C Esquinas
- Departamento Clínico, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Laureate Universities, Madrid, España
| | - D Nikolavsky
- Departmento de Urología, State University of New York Upstate Medical University, Syracuse, NY, EE.UU
| | - N Martins
- Departamento de Urología, Universidad de Lisboa, Hospital de Santa María, Lisboa, Portugal
| | - F Martins
- Departamento de Urología, Universidad de Lisboa, Hospital de Santa María, Lisboa, Portugal
| |
Collapse
|
35
|
Silva AL, Ourique C, Martins F, Friões F. [Syndrome of Irreversible Lithium-Effectuated NeuroToxicity]. ACTA MEDICA PORT 2017; 30:151-153. [PMID: 28527484 DOI: 10.20344/amp.7907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Accepted: 08/11/2016] [Indexed: 11/20/2022]
Abstract
Lithium has a narrow therapeutic window. Frequent monitoring of both serum levels and clinical signs of toxicity is warranted because toxicity may be present even when concentrations are within the therapeutic range. We report the case of a man with lithium poisoning, with persistent neurologic signs and symptoms even after removal of lithium from circulation - a diagnosis of syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) was made.
Collapse
Affiliation(s)
- Ana Luísa Silva
- Serviço de Medicina Interna. Centro Hospitalar de São João. Porto. Portugal
| | - Carolina Ourique
- Serviço de Medicina Interna. Centro Hospitalar de São João. Porto. Portugal
| | - Filipe Martins
- Serviço de Medicina Interna. Centro Hospitalar de São João. Porto. Portugal
| | - Fernando Friões
- Unidade de Cuidados Intermédios de Medicina. Centro Hospitalar de São João. Porto. Portugal
| |
Collapse
|
36
|
Cushing JM, Martins F, Pinto AA, Veprauskas A. A bifurcation theorem for evolutionary matrix models with multiple traits. J Math Biol 2017; 75:491-520. [DOI: 10.1007/s00285-016-1091-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Revised: 10/03/2016] [Indexed: 11/25/2022]
|
37
|
Tenreiro P, Rebelo S, Martins F, Santos M, Coelho ED, Almeida M, Alves de Matos AP, da Cruz E Silva OAB. Comparison of simple sucrose and percoll based methodologies for synaptosome enrichment. Anal Biochem 2016; 517:1-8. [PMID: 27771393 DOI: 10.1016/j.ab.2016.10.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 09/16/2016] [Accepted: 10/18/2016] [Indexed: 01/20/2023]
Abstract
Synaptosomes are isolated nerve terminals. They represent an extremely attractive in vitro model system to study synaptic physiology since they preserve morphological and functional characteristics of the synapse. As such they have been used to investigate synaptic dysfunctions associated with neuropathologies like Alzheimer's disease. In the present work two simple methodologies for isolating synaptosomal-enriched fractions were compared for the first time. The starting points of both protocols were rat cortical or hippocampal homogenized tissues that underwent several differential centrifugation steps followed by a final purification of synaptosomal-enriched fractions using either a Percoll gradient or a Sucrose gradient. Comparison of the fractions obtained was carried out, using both biochemical and electron microscopy approaches. In the biochemical analysis the protein levels of pre-synaptic, post-synaptic, nuclear and mitochondrial markers were evaluated. Additional characterization of the synaptosomal-enriched fractions was performed using transmission electron microscopy. In summary, the results indicate that under the conditions tested the Sucrose based protocol is more efficient for the isolation of synaptosomal-enriched fractions from both neuronal tissues, being particularly efficient for hippocampus that is a less abundant brain tissue. Further, the sucrose protocol apparently results in a higher yield of viable synaptosomes suitable for further assays, including structural and functional studies of synapses; making this an attractive procedure to study processes associated with neuropathologies.
Collapse
Affiliation(s)
- P Tenreiro
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| | - S Rebelo
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal.
| | - F Martins
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| | - M Santos
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| | - E D Coelho
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| | - M Almeida
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| | - A P Alves de Matos
- Centro de Estudos do Ambiente e do Mar, Faculdade de Ciências da Universidade de Lisboa, Portugal; Centro de Investigação Interdisciplinar Egas Moniz, Monte de Caparica, Lisboa, Portugal
| | - O A B da Cruz E Silva
- Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
| |
Collapse
|
38
|
Abstract
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by Prchal and Axelrad in the mid-1970s. The knowledge on this mutation brought an important insight to our understanding of PV pathogenesis and led to a revision of the World Health Organization diagnostic criteria in 2008. JAK-STAT is a major signaling pathway implicated in survival and proliferation of hematopoietic precursors. High prevalence of JAK2 V617F mutation among myeloproliferative neoplasms (>95% in PV and ~50% in primary myelofibrosis and essential thrombocythemia) together with its role in constitutively activating JAK-STAT made JAK2 a privileged therapeutic target. Ruxolitinib, a JAK 1 and 2 inhibitor, has already proven to be efficient in relieving symptoms in primary myelofibrosis and PV. In the latter, it also appears to improve microvascular involvement. However, evidence regarding its potential role in altering the natural course of PV and its use as an adjunct to current standard therapies is sparse. Therapeutic advances are needed in PV as phlebotomy, low-dose aspirin, cytoreductive agents, and interferon alpha are the only therapeutic tools available at the moment to influence outcome. Even though several questions are still unanswered, this review aims to serve as an overview article of the potential role of ruxolitinib in PV according to current literature and expert opinion. It should help hematologists to visualize the place of this tyrosine kinase inhibitor in the field of current practice and offer criteria for a careful patient selection.
Collapse
Affiliation(s)
- Sabine Blum
- Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland
| | - Filipe Martins
- Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland
| | - Lorenzo Alberio
- Service and Central Laboratory of Hematology, CHUV, University Hospital of Lausanne, Lausanne, Switzerland
| |
Collapse
|
39
|
Martins F, Berthold D. [Metastatic renal cell carcinoma, back to the future]. Rev Med Suisse 2016; 12:994-998. [PMID: 27424427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Renal cell carcinoma (RCC) is composed of several histopathological entities. There are more than 1,000 new cases in Switzerland every year, one third of which are diagnosed at an advanced stage. The development of chemotherapy had no impact on its overall prognosis. Since the mid-2000s, treatment of metastatic RCC was transformed by the arrival of targeted therapies. In the early 90s, high dose interleukine-2 (IL-2) allowed first cases of complete response, demonstrating the immunogenicity of RCC. More than twenty years after its first steps, immunotherapy progressed due to the recently approved nivolumab (an anti-PD1 monoclonal antibody) in second line of treatment. This review outlines the progress that has been made in the understanding and treatment of this pathology.
Collapse
|
40
|
Martins F, Orcurto A, Michielin O, Coukos G. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Rev Med Suisse 2016; 12:989-993. [PMID: 27424426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Adoptive cell therapy consists in the use of T lymphocytes for therapeutic purposes. Up to now, of limited use in clinical practice for logistical reasons, technical progress and substantial level of evidence obtained in the last decade allow its arrival in universitary hospitals. We will principally discuss the administration of expanded tumor infiltrating T cells in the treatment of metastatic melanoma. This treatment modality exploits the natural specificity of these cells and aims to potentiate their effectiveness. This personalized immunotherapy detains a potential for expansion to many other advanced tumor types.
Collapse
|
41
|
Brun B, Martins F, Faniel S, Hackens B, Cavanna A, Ulysse C, Ouerghi A, Gennser U, Mailly D, Simon P, Huant S, Bayot V, Sanquer M, Sellier H. Electron Phase Shift at the Zero-Bias Anomaly of Quantum Point Contacts. Phys Rev Lett 2016; 116:136801. [PMID: 27081995 DOI: 10.1103/physrevlett.116.136801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Indexed: 06/05/2023]
Abstract
The Kondo effect is the many-body screening of a local spin by a cloud of electrons at very low temperature. It has been proposed as an explanation of the zero-bias anomaly in quantum point contacts where interactions drive a spontaneous charge localization. However, the Kondo origin of this anomaly remains under debate, and additional experimental evidence is necessary. Here we report on the first phase-sensitive measurement of the zero-bias anomaly in quantum point contacts using a scanning gate microscope to create an electronic interferometer. We observe an abrupt shift of the interference fringes by half a period in the bias range of the zero-bias anomaly, a behavior which cannot be reproduced by single-particle models. We instead relate it to the phase shift experienced by electrons scattering off a Kondo system. Our experiment therefore provides new evidence of this many-body effect in quantum point contacts.
Collapse
Affiliation(s)
- B Brun
- Université Grenoble Alpes, F-38000 Grenoble, France
- CNRS, Institut NEEL, F-38042 Grenoble, France
| | - F Martins
- IMCN/NAPS, Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
| | - S Faniel
- IMCN/NAPS, Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
| | - B Hackens
- IMCN/NAPS, Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
| | - A Cavanna
- CNRS, Laboratoire de Photonique et de Nanostructures, UPR20, F-91460 Marcoussis, France
| | - C Ulysse
- CNRS, Laboratoire de Photonique et de Nanostructures, UPR20, F-91460 Marcoussis, France
| | - A Ouerghi
- CNRS, Laboratoire de Photonique et de Nanostructures, UPR20, F-91460 Marcoussis, France
| | - U Gennser
- CNRS, Laboratoire de Photonique et de Nanostructures, UPR20, F-91460 Marcoussis, France
| | - D Mailly
- CNRS, Laboratoire de Photonique et de Nanostructures, UPR20, F-91460 Marcoussis, France
| | - P Simon
- Laboratoire de Physique des Solides, Université Paris-Sud, F-91405 Orsay, France
| | - S Huant
- Université Grenoble Alpes, F-38000 Grenoble, France
- CNRS, Institut NEEL, F-38042 Grenoble, France
| | - V Bayot
- Université Grenoble Alpes, F-38000 Grenoble, France
- IMCN/NAPS, Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
| | - M Sanquer
- Université Grenoble Alpes, F-38000 Grenoble, France
- CEA, INAC-SPSMS, F-38054 Grenoble, France
| | - H Sellier
- Université Grenoble Alpes, F-38000 Grenoble, France
- CNRS, Institut NEEL, F-38042 Grenoble, France
| |
Collapse
|
42
|
Descombes E, Martins F, Hemett OM, Erard V, Chuard C. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. BMC Pharmacol Toxicol 2016; 17:4. [PMID: 26846675 PMCID: PMC4743204 DOI: 10.1186/s40360-016-0048-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 01/27/2016] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy. METHODS Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined before (n = 30) and after (n = 17) dialysis by liquid chromatography-mass spectrometry. RESULTS Overall, the mean ± SD dose of cefepime was 920 ± 270 mg (14.5 ± 5.1 mg/kg), but it was significantly lower before the 48 h interval (775 ± 210 mg or 12.7 ± 4.5 mg/kg) compared to the 72 h interval (1125 ± 225 mg or 17.2 ± 4.9 mg/kg) (p < 0.05). The mean trough pre-dialysis concentrations were 10.7 ± 3.9 mg/l and 11.3 ± 5.6 mg/l at 48 and 72 h, respectively. These levels always largely exceeded the EUCAST susceptibility breakpoints for all the targeted bacteria (>1 mg/l) with the exception of Pseudomonas aeruginosa (>8 mg/l). Cefepime concentrations were higher in anuric patients compared to those with preserved diuresis (15.6 ± 3.5 vs 9.25 ± 3.6 mg/l; p < 0.001) and decreased on average by 81 % during dialysis (from 10.5 ± 3.7 to 1.96 ± 1.2 mg/l; p < 0.001). The clinical outcome of all patients was good. CONCLUSIONS Outpatient treatment with cefepime administered post-dialysis three-times-weekly was effective and well-tolerated in our patients. According to our data, in patients infected by highly susceptible pathogens a fixed dose of cefepime of 1 g before every 48-h interval and of 1.5 g before every 72-h interval should be recommended, without need of routine monitoring of the cefepime blood levels. In patients having an infection with less susceptibles pathogens as P. aeruginosa, and particularly in those among them exhibiting residual renal function, higher initial doses are necessary (1.5 g before a 48-h interval and 2.0 g before a 72-h interval) with adaption according to the subsequent pre-dialysis trough serum levels.
Collapse
Affiliation(s)
- Eric Descombes
- Service of Nephrology, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland.
| | - Filipe Martins
- Service of Nephrology, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland.
| | - Ould Maouloud Hemett
- Service of Nephrology, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland.
| | - Veronique Erard
- Service of Infectious Diseases, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland.
| | - Christian Chuard
- Service of Infectious Diseases, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland.
| |
Collapse
|
43
|
|
44
|
Martins F, Ourique C, Faria da Costa J, Nuak J, Braz V, Pereira E, Sarmento A, Almeida J. Cerebral Salt Wasting Syndrome and Systemic Lupus Erythematosus: Case Report. J Med Cases 2016. [DOI: 10.14740/jmc2615w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
45
|
Yuan A, Chai X, Martins F, Arai S, Arora M, Correa ME, Pidala J, Cutler CS, Lee SJ, Treister NS. Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. Oral Dis 2015; 22:235-40. [PMID: 26708609 DOI: 10.1111/odi.12429] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 11/25/2015] [Accepted: 12/16/2015] [Indexed: 01/03/2023]
Abstract
OBJECTIVES This study evaluated the extent to which oral chronic graft-versus-host disease (cGVHD) consensus assessments are predictive of management across institutions with and without oral medicine (OM) centers, and whether ancillary care guidelines are followed within clinical practice. METHODS Longitudinal oral cGVHD data were abstracted from the cGVHD Consortium, and additional mouth-specific management data were analyzed across five transplant centers. RESULTS Seventy-nine patients with 656 visits were observed for a median of 7.1 months with one visit per follow-up month. Ancillary therapies for oral cGVHD were prescribed for 67% of patients for a median of 0.46 months (per follow-up month) at OM centers and 0.78 months at non-OM centers. Patients treated with ancillary therapy were more likely to have an National Institutes of Health (NIH) mouth score of ≥1 (P < 0.001, odds ratio: 5.1) and mouth pain (P = 0.01, odds ratio: 2.6). The odds ratios of receiving ancillary therapy from OM experts were higher than transplant physicians (53%; P = 0.03). CONCLUSIONS Oral cGVHD consensus assessments corresponding with ancillary therapy use were mouth pain and NIH mouth score, with higher odds ratios of receiving therapy from OM experts. Ancillary care guidelines for oral cGVHD are reflected in academic clinical practice with respect to utilization of recommended prescriptions.
Collapse
Affiliation(s)
- A Yuan
- Division of Oral Medicine, Brigham and Women's Hospital, Boston, MA, USA.,Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
| | - X Chai
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - F Martins
- Department of Oral Pathology and Oral Diagnosis, University of São Paulo School of Dentistry, São Paulo, Brazil
| | - S Arai
- Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
| | - M Arora
- Department of Medicine, University of Minnesota, Boston, MA, USA
| | - M E Correa
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Oral Medicine Ambulatory, Bone Marrow Transplantation Unit, Hematology and Blood Transfusion Center, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - J Pidala
- Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA
| | - C S Cutler
- Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
| | - S J Lee
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - N S Treister
- Division of Oral Medicine, Brigham and Women's Hospital, Boston, MA, USA.,Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
| |
Collapse
|
46
|
Martins F, Gonçalves R, Oliveira J, Cruz-Monteagudo M, Nieto-Villar JM, Paz-y-Miño C, Rebelo I, Tejera E. Unravelling the relationship between protein sequence and low-complexity regions entropies: Interactome implications. J Theor Biol 2015; 382:320-7. [PMID: 26164061 DOI: 10.1016/j.jtbi.2015.06.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 06/12/2015] [Accepted: 06/28/2015] [Indexed: 10/23/2022]
Abstract
Low-complexity regions are sub-sequences of biased composition in a protein sequence. The influence of these regions over protein evolution, specific functions and highly interactive capacities is well known. Although protein sequence entropy has been largely studied, its relationship with low-complexity regions and the subsequent effects on protein function remains unclear. In this work we propose a theoretical and empirical model integrating the sequence entropy with local complexity parameters. Our results indicate that the protein sequence entropy is related with the protein length, the entropies inside and outside the low-complexity regions as well as their number and average size. We found a small but significant increment in the sequence entropy of hubs proteins. In agreement with our theoretical model, this increment is highly dependent of the balance between the increment of protein length and average size of the low-complexity regions. Finally, our models and proteins analysis provide evidence supporting that modifications in the average size is more relevant in hubs proteins than changes in the number of low-complexity regions.
Collapse
Affiliation(s)
- F Martins
- Department of Biochemistry, Faculty of Pharmacy, University of Porto, Portugal
| | - R Gonçalves
- Department of Biochemistry, Faculty of Pharmacy, University of Porto, Portugal
| | - J Oliveira
- Department of Biochemistry, Faculty of Pharmacy, University of Porto, Portugal
| | - M Cruz-Monteagudo
- Instituto de Investigaciones Biomédicas, Universidad de las Américas, Quito, Ecuador
| | - J M Nieto-Villar
- Dpto. de Química-Física, Fac. de Química, Universidad de La Habana, Cuba. Cátedra de Sistemas Complejos "H. Poincaré", Universidad de La Habana, Cuba
| | - C Paz-y-Miño
- Instituto de Investigaciones Biomédicas, Universidad de las Américas, Quito, Ecuador
| | - I Rebelo
- Department of Biochemistry, Faculty of Pharmacy, University of Porto, Portugal; UCIBIO@REQUIMTE, Portugal.
| | - E Tejera
- Instituto de Investigaciones Biomédicas, Universidad de las Américas, Quito, Ecuador
| |
Collapse
|
47
|
Generoso S, Trindade L, Andrade F, Rodrigues N, Almeida-Leite C, Cardoso V, Martins F, Maioli T. MON-PP094: Treatment with Symbiotic Protects Intestinal Damage in an Experimental Model of Mucositis. Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30526-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Pires C, Cavaco A, Martins F, Vigário M. Using an Automatic Tool to Identify Potential Readability Issues in a Large Sample of Medicinal Package Inserts. Methods Inf Med 2015; 54:379-81. [PMID: 26108873 DOI: 10.3414/me15-04-0003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Accepted: 05/29/2015] [Indexed: 11/09/2022]
Affiliation(s)
- C Pires
- C. Pires, MSc, PhD Student, Research Institute for Medicines(iMed.ULisboa), Faculty of Pharmacy Department of Social Pharmacy University of Lisbon, Avenida Professor Gama Pinto 1170-139, Lisbon, Portugal, E-mail:
| | | | | | | |
Collapse
|
49
|
Oliveira Ramos F, Eusébio M, Martins F, Cordeiro I, Mourão A, Salvador M, Cerqueira M, Brito I, Lucas R, Canhão H, Santos M, Melo Gomes J, Fonseca J. OP0022 Juvenile Idiopathic Arthritis in Adulthood: Clinical Pattern and Long-Term Outcomes of 512 Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2881] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Mourão A, Santos M, Melo Gomes J, Martins F, Mendonça S, Ramos F, Fernandes S, Salgado M, Guedes M, Carvalho S, Costa J, Brito I, Duarte C, Furtado C, Sequeira G, Lopes A, Rodrigues A, Branco J, Fonseca J, Canhão H. SAT0494 Long-Term Retention and Predictors of Anti-Tnf Treatment Response in Juvenile Idiopathic Arthritis: Data from Reuma.PT, a Nation-Wide Register. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|